Pediatric Hematology/Oncology Fellowship
Johns Hopkins University/National Cancer Institute Pediatric Hematology/Oncology Fellowship
Training Program
- Fellowship Program Overview
- Information For Applicants
- To apply: Applicants for Fellowship training beginning in July 2011 will apply via ERAS. Please visit http://www.aamc.org/students/eras/start.htm for instructions.
- Questions? Please feel free to contact Gladys Valencia Novak, Fellowship Coordinator at (410) 614-5055 or email.
Overview
Beginning with the group starting in July 2006, seven fellows per year are selected via the National Residency Matching Program (NRMP) to train each year in the program. The fellowship is designed to provide clinical and research exposure that allows for the development of subspecialist academicians adept in laboratory and/or clinical research, coupled with superior patient management skills. Training in Pediatric Oncology at Johns Hopkins University (JHU) is under the supervision of Dr. Kenneth J. Cohen, Director of Fellowship Training and Clinical Director of Pediatric Oncology. Training in Pediatric Hematology is under the direction of Dr. James F. Casella, Chief of Pediatric Hematology and Co-Director of Fellowship Training at JHU. Training in Pediatric Oncology at the National Cancer Institute (NCI), National Institutes of Health (NIH) is under the direction of Dr. Alan S. Wayne, Co-Director of Fellowship Training and Clinical Director of the Pediatric Oncology Branch (POB). The first year of the fellowship is largely clinical with inpatient and outpatient exposure at JHU and the NIH. The second and third years are focused research years allowing for training in laboratory and/or clinical research.
Clinical Training
The first year fellowship will include:
- JHU Hematology Inpatient Service
- JHU Hematology Outpatient Service
- JHU Hematology Laboratory Training
- JHU Oncology Service (Green and Blue Team)
- NIH Inpatient Oncology
- NIH Outpatient Oncology
- Continuity Clinic (weekly during selected rotations)
- Vacation
JHU Hematology Inpatient Service: This rotation is designed to educate fellows in the treatment of a wide range of hematologic conditions including patients with hemoglobinopathies, coagulopathies, ITP, anemias, and patients requiring chronic transfusions. Fellows are responsible for supervising the care of all inpatients on the hematology service. Additional exposures include teaching in the preparation and interpretation of blood smears and bone marrows.
JHU Hematology Outpatient Service: Exposures during this rotation in hematology includes the evaluation of outside referrals for a wide range of hematologic conditions, and participation in the longitudinal management of children with defined hematologic disorders. Fellows will also have specific responsibilities for the management of patients undergoing erythrocytopheresis.
JHU Hematology Laboratory Training: Rotations are spent in hematology laboratories exposure to Coagulation Lab, Hemoglobinopathies/Routine Hematology, and Blood Bank. The purpose of these laboratory exposures are designed to familiarize the fellow with the gamut of laboratory studies required for hematologic interpretation and diagnoses. Fellows participate in supporting conferences (e.g. coagulation conference).
JHU Oncology Service: Fellows work on the Green Team (Oncology) followed by the Blue Team (BMT). The Green team fellow supervises the care of newly diagnosed patients, patients with therapy-associated complications,and patients receiving inpatient chemotherapy. Exposure to the broad range of oncologic diagnoses is anticipated. Outpatient exposures during this time include the evaluation of outpatient referrals, assessment of neuro-oncology patients, and evaluation of patients with late-effects related to prior cancer treatment. During the Blue team rotation, fellows will be responsible for the oversight of patients undergoing BMT, as well as patients admitted for complications related to prior transplantation. Outpatient exposures will include the evaluation of patients being considered for BMT as well as some participation in the ongoing management of established BMT patients. Fellows have responsibility for the supervision of houseofficers who rotate on the service each month. Newly diagnosed patients are assigned to the fellow for ongoing continuity in the outpatient setting.
NIH Inpatient Oncology: Inpatient oncology at the NIH allow fellows to care for patients who are hospitalized for specific therapy or complications of treatment. Patients admitted are treated on NCI clinical trials. Fellows are directly supervised by the attending physician and have extensive interactions with research protocol principal investigators. This interaction emphasizes the important connection between research, education and patient care.
NIH Outpatient Oncology: Fellows are responsible for clinical care of POB outpatients. They evaluate new referrals and provide comprehensive care for patients undergoing treatment or evaluation. POB patients are entered on clinical research protocols. The POB offers a second-opinion service and fellows are responsible for the initial evaluation of these patients. In many instances, the fellow provides continuity of patient care from the inpatient to the outpatient setting.
Continuity Clinic: Fellows are required by the subspecialty board to maintain a continuity exposure during their fellowship. All fellows will have continuity clinic at JHU, which will be composed of patients acquired during their inpatient and outpatient rotations at JHU. During the first year of fellowship, continuity clinic will take place during selected months. In subsequent years of training, the fellow will individually tailor their continuity experience which will occur at JHU regardless of research locale.
Vacation: Approximately four weeks of vacation are provided per year.
Training in the Second and Third Years
The second and third years of fellowship are designed to be focused research years. To ensure maximum productivity, clinical responsibilities are limited to one-half day of continuity clinic each week and periodic weekend call on the hematology service. The remainder of this protected time is spent pursuing a research initiative tailored to the specific interests of the fellow. Decisions regarding the appropriate locale for research training are made in concert with faculty advisors and fellowship directors. Many fellows focus on basic science research, either in the laboratories of faculty members in Pediatric Hematology/Oncology at either institution or in other appropriate laboratory settings. Fellows are free to choose among the many laboratories at JHU and throughout the intramural NIH community. Selected fellows who have chosen to focus on clinical research may apply to the clinical research program at the JHU Bloomberg School of Public Health where formal training and a clinical research experience is provided in the expectation of fellows obtaining a PhD in Clinical Investigation. Fellows may also apply for advanced studies in clinical research through an NIH/POB program providing up to three years of additional research training following the completion initial three years of fellowship training.
Among the many advantages of the merger is the wide range of research opportunities available to each fellow. Laboratory and clinical research at both institutions are unparalleled and the merger allows the fellow to choose among almost unlimited research options.
Primary Clinical Faculty and Research Interests:
Faculty Member Institution Research Focus
Robert J. Arceci, MD, PhD JHU Development of novel targets and immunotherapies
for leukemias and histocytic disorders
Kristen Baird, MD NIH Biology and treatment of chronic gravt-vs.-host disease
Patrick Brown, MD JHU Molecularly targeted therapies for leukemia
Emily Barron-Casella, PhD JHU Study of platelet surface glycoproteins involved in NAIT
James Casella, MD JHU Regulation of actin polymerization and the role of
platelet glycoproteins in alloimmune thrombocytopenia;
clinical trials in sickle cell disease
Allen R. Chen, MD, PhD JHU Translational studies in BMT
Kenneth J. Cohen, MD, MBA JHU Clinical and translational neuro-oncology research
Jason Farrar, MD JHU Bone marrow failure and epigenetic changes in
leukemia
Elizabeth Fox, MD NIH Clinical pharmacology and drug development
Alan D. Friedman, MD JHU Transcriptional regulation of myeloid differentiation and
action of myeloid oncoproteins
Christopher Gamper, MD, PhD JHU Regulation of T cell effector differentiation and
tolerance
Lee J. Helman, MD NIH Molecular pathogenesis and immunotherapy of
sarcomas
Gregory Kato, MD NIH Translational studies in sickle cell disease
Jeffrey Keefer, MD, PhD JHU Regulation of fetal hemoglobin
Javed Khan, MD NIH Pediatric cancer genomics
Chand Khanna, DVM, PhD NIH Tumor metastasis biology, comparative oncology
Jason Levine, MD NIH Bioinformatic systems for translational research
David M. Loeb, MD, PhD JHU Molecular biology of AML and translational studies in
sarcoma treatment
Crystal Mackall, MD NIH Immune reconstitution, immunotherapy
Ido Paz-Priel, MD JHU Transcriptional Regulation in leukemia
Donald Small, MD, PhD JHU Molecular biology of normal hematopoiesis and
leukemia
J.J. Strouse, MD JHU Complications and clinical trials in sickle cell disease
and hemophilia, and epidemiology of pediatric
melanoma
Heather Symons, MD JHU Translational studies in BMT; research in palliative care
Carol J. Thiele, PhD NIH Molecular biology of neuroectodermal tumors,
regulation of cellular differentiation pathways
Clifford Takemoto, MD JHU Transcription factors and growth factor signaling in
hematopoietic development
Katherine Warren, MD NIH Neuro-oncology, neuro-imaging, and neurotoxicity
research
Alan S. Wayne, MD NIH Targeted and immune-based therapies for
hematopoietic malignancies
Brigitte Widemann, MD NIH Clinical pharmacology and new drug development for
children with cancer and neurofibromatosis Type 1
Lori Wiener, PhD NIH Pediatric psychosocial research
Elias Zambidis, MD, PhD JHU Human developmental hematopoiesis and embryonic
stem cell biology
